Clinical & Experimental Cardiology
Open Access
ISSN: 2155-9880
ISSN: 2155-9880
Salma Abdelrahman
Ain Shams University, Cairo, Egypt
Posters & Accepted Abstracts: J Clin Exp Cardiolog
Statement: Cardiovascular disease remains the leading cause of death in Egypt. While statins are well-established for lipid-lowering, recent interest has emerged in their anti-inflammatory properties, particularly in postmyocardial infarction (MI) patients. This study aimed to evaluate the effect of high-intensity statin therapy on inflammatory markers, specifically high-sensitivity C-reactive protein (hs-CRP), in Egyptian patients following acute MI. Methodology: A prospective, controlled study was conducted at Ain Shams University Hospitals in Cairo between February 2023 and February 2024. A total of 120 post-MI patients were enrolled and divided into two groups: Group A (n=60) received atorvastatin 80 mg daily, and Group B (n=60) received simvastatin 40 mg daily. hs-CRP levels were measured at baseline, and then again at 4 weeks and 12 weeks post-therapy using an ELISA-based method. Patients were followed for recurrence of symptoms or major adverse cardiovascular events (MACE). Results: Baseline hs-CRP levels were comparable between groups (p > 0.05). After 12 weeks, Group A demonstrated a significantly greater reduction in hs-CRP levels (from 5.6 ± 1.2 mg/L to 2.1 ± 0.7 mg/L) compared to Group B (from 5.4 ± 1.3 mg/L to 3.4 ± 0.9 mg/L), with p < 0.001. Additionally, MACE occurrence was lower in Group A (6.7%) versus Group B (13.3%), though not statistically significant (p = 0.2). Conclusion: High-intensity atorvastatin therapy significantly reduces systemic inflammation as indicated by hs-CRP in post-MI patients in Egypt. These findings support the broader implementation of high-dose statins in post-MI management for secondary prevention beyond lipid-lowering.